Jade Biosciences (NASDAQ:JBIO) Shares Gap Up - What's Next?

Key Points

• JBIO shares gapped higher at the open, rising from a prior close of $22.55 to $23.82 before trading at $21.5780 on volume of 37,273 shares.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $51.75 price target, though individual ratings range from Strong Buy to Sell.
• Jade Biosciences reported a quarterly loss of $0.76 per share, missing the $0.66 consensus estimate; analysts expect a full-year loss of approximately $2.84 per share.

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $22.55, but opened at $23.82. Jade Biosciences shares last traded at $21.5780, with a volume of 37,273 shares changing hands.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JBIO shares. Piper Sandler set a $55.00 target price on shares of Jade Biosciences in a report on Tuesday, June 2nd. Wall Street Zen downgraded shares of Jade Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. BTIG Research boosted their price target on shares of Jade Biosciences from $74.00 to $77.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Weiss Ratings cut shares of Jade Biosciences from a "sell (d)" rating to a "sell (d-)" rating in a research note on Tuesday, June 16th. Finally, Guggenheim reaffirmed a "buy" rating and set a $47.00 price objective on shares of Jade Biosciences in a report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.75.

Jade Biosciences Price Performance

The business has a 50 day simple moving average of $20.71 and a 200 day simple moving average of $18.93. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -11.08 and a beta of 1.49.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.10). As a group, sell-side analysts anticipate that Jade Biosciences, Inc. will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Jade Biosciences

Institutional investors have recently modified their holdings of the stock. Legal & General Group Plc acquired a new stake in shares of Jade Biosciences in the second quarter valued at approximately $29,000. Russell Investments Group Ltd. acquired a new position in Jade Biosciences during the 2nd quarter worth $31,000. BNP Paribas Financial Markets bought a new position in Jade Biosciences in the 2nd quarter valued at $32,000. California State Teachers Retirement System boosted its position in Jade Biosciences by 40.3% in the 4th quarter. California State Teachers Retirement System now owns 2,850 shares of the company's stock valued at $44,000 after buying an additional 819 shares during the last quarter. Finally, Group One Trading LLC increased its stake in shares of Jade Biosciences by 122.9% in the 4th quarter. Group One Trading LLC now owns 4,195 shares of the company's stock valued at $65,000 after buying an additional 22,527 shares during the period.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source